Corient Private Wealth LP Makes New $17.06 Million Investment in Avantor, Inc. $AVTR

Corient Private Wealth LP acquired a new position in shares of Avantor, Inc. (NYSE:AVTR) in the second quarter, HoldingsChannel reports. The institutional investor acquired 1,722,983 shares of the company’s stock, valued at approximately $17,058,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AVTR. Royal Bank of Canada lifted its holdings in Avantor by 104.3% during the 1st quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock worth $3,302,000 after purchasing an additional 104,022 shares during the last quarter. Empowered Funds LLC grew its holdings in Avantor by 40.3% in the 1st quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock valued at $286,000 after buying an additional 5,075 shares in the last quarter. Cetera Investment Advisers grew its holdings in Avantor by 40.2% in the 2nd quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock valued at $542,000 after buying an additional 11,543 shares in the last quarter. Quantbot Technologies LP bought a new position in Avantor during the 2nd quarter worth $232,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Avantor by 214.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock worth $1,670,000 after buying an additional 84,679 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AVTR has been the subject of a number of recent research reports. Sanford C. Bernstein assumed coverage on shares of Avantor in a research report on Friday, June 26th. They issued a “market perform” rating and a $10.50 target price for the company. Barclays raised their price target on shares of Avantor from $7.00 to $8.00 and gave the stock an “underweight” rating in a research report on Wednesday, June 24th. TD Cowen restated a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Evercore set a $10.50 price objective on Avantor in a report on Monday, July 6th. Finally, Citigroup boosted their target price on shares of Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.00.

Avantor Trading Down 0.1%

AVTR opened at $14.60 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18. Avantor, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $15.93. The company’s 50 day moving average price is $12.12 and its two-hundred day moving average price is $9.77. The firm has a market capitalization of $9.87 billion, a price-to-earnings ratio of -17.38, a PEG ratio of 11.03 and a beta of 0.89.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.Avantor’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, research analysts predict that Avantor, Inc. will post 0.81 earnings per share for the current year.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.